# TACE Combined With Tyrosine Kinase Inhibitors and Tislelizumab in Unresectable Hepatocellular Carcinoma

> **NCT06232759** · PHASE2 · COMPLETED · sponsor: **Guangxi Medical University** · enrollment: 56 (actual)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** Transarterial chemoembolization combined with Tyrosine Kinase Inhibitors and Tislelizumab

## Key facts

- **NCT ID:** NCT06232759
- **Lead sponsor:** Guangxi Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-04-01
- **Primary completion:** 2023-10-30
- **Final completion:** 2024-01-20
- **Target enrollment:** 56 (ACTUAL)
- **Last updated:** 2024-06-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06232759

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06232759, "TACE Combined With Tyrosine Kinase Inhibitors and Tislelizumab in Unresectable Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06232759. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*